Entrada Therapeutics (TRDA) closed at $5.25 on November 10, 2026, up 11.9% from the previous close, on volume of 565,420 shares (30-day average 395,598).
Data as of November 10, 2026.
Entrada Therapeutics GAAP EPS of -$0.94 beats by $0.07, revenue of $0.90M misses by $4.97M
Seeking Alpha News (Thu, 5-Nov 8:00 AM ET)
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
TRDA Moves Toward Its Top Dose in ELEVATE-44-201 After DMC Backs 18 mg/kg Cohort 3
Market Chameleon (Wed, 14-Oct 7:15 AM ET)
Globe Newswire (Wed, 14-Oct 7:00 AM ET)
Globe Newswire (Wed, 14-Oct 7:00 AM ET)
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Globe Newswire (Thu, 10-Sep 7:00 AM ET)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 2-Sep 4:30 PM ET)
Entrada Therapeutics Highlights Strong Pipeline Momentum and Solid Cash Runway Through Q3 2027
Market Chameleon (Thu, 7-May 3:41 AM ET)
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics trades on the NASDAQ stock market under the symbol TRDA.
As of November 10, 2026, TRDA stock price climbed to $5.25 with 565,420 million shares trading.
TRDA has a beta of -0.47, meaning it tends to be less sensitive to market movements. TRDA has a correlation of 0.00 to the broad based SPY ETF.
TRDA has a market cap of $205.54 million. This is considered a Small Cap stock.
Last quarter Entrada Therapeutics reported $905,000 in Revenue and -$.94 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.05.
In the last 3 years, TRDA traded as high as $21.79 and as low as $4.11.
The top ETF exchange traded funds that TRDA belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
TRDA has underperformed the market in the last year with a return of -24.0%, while the SPY ETF gained +12.9%. In the last 3 month period, TRDA fell short of the market, returning -23.6%, while SPY returned -2.8%. However, in the most recent 2 weeks TRDA has outperformed the stock market by returning +10.5%, while SPY returned -2.0%.
TRDA support price is $4.36 and resistance is $5.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRDA shares will trade within this expected range on the day.
